Want to see FR:OSE full AI Analyst Report?
OSE Stock Chart & Stats
€3.22
€0.05(1.46%)
At close: 4:00 PM EDT
€3.22
€0.05(1.46%)
Day’s Range― - ―
52-Week Range€2.54 - €7.70
Previous CloseN/A
Volume102.94K
Average Volume (3M)137.07K
Market Cap
€61.50M
Enterprise Value€102.63M
Total Cash (Recent Filing)€22.65M
Total Debt (Recent Filing)€35.38M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume136,856
30 Day Avg. Volume137,071
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)€6.17M
Bulls Say, Bears Say
Bulls Say
Immunotherapy Pipeline FocusThe company is focused on therapeutic areas with multiple development stages, spanning oncology and immune-inflammatory diseases. Progressing antibody-based and T-cell-targeted candidates through research and clinical development provides a foundation for potential future milestones and partnership opportunities.
Strong 2024 Cash GenerationThe 2024 results demonstrate that the business has previously generated substantial operating and free cash flow when revenue and profitability were strong. That historical capacity could support development activity and indicates the model can produce meaningful cash inflows under favorable commercial conditions.
Leverage Improved Versus 2023Although current leverage remains a concern, improvement from the more leveraged 2023 position shows that the balance sheet has not deteriorated continuously. This provides some evidence of prior deleveraging progress and may help preserve financial flexibility if operating performance stabilizes.
Bears Say
Severe Revenue And Earnings VolatilityThe sharp reversal from substantial 2024 revenue and profitability to a very small 2025 revenue base and heavy losses indicates highly unstable earnings power. Such volatility makes planning and funding development programs more difficult and weakens confidence in near-term operating sustainability.
Significant Cash BurnThe swing from strong positive cash generation to substantial operating and free-cash-flow burn increases the company’s funding dependency. If negative cash flow persists, more resources may need to be directed toward financing rather than advancing the immunotherapy pipeline or strengthening the business.
Debt Exceeds Eroded EquityDebt exceeding equity, combined with a sharply reduced capital base, increases financial risk while the company is loss-making. Persistent losses could further erode equity and constrain capital allocation, leaving less balance-sheet capacity to absorb setbacks or fund ongoing development.
OSE Immunotherapeutics SA News
OSE FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was €2.54 and its highest was €7.70 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €61.50M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Sep 28, 2026 which is in 10 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -€1.007 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€1.007 in its last earnings report. Following the earnings report the stock price went down -3.288%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in FR:OSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.